Jun 20, 2024 · Arcturus Therapeutics is a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and …

Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense …

In a wholly owned program, Arcturus is developing a messenger RNA (mRNA) medicine to treat ornithine transcarbamylase deficiency, a life-threatening genetic disease that affects over …

RNA, DNA and enzymes are rapidly degraded in the gut and in the blood stream. Arcturus’s proprietary LUNAR ® technology can be used to deliver gene editing tools directly into target …

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to …

The latest news and publications for Arcturus Therapeutics, including vaccine news, COVID-19 publications, rare disease scientific publications including Ornithine Transcarbamylase, Cystic …

Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA …

Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA …

Arcturus’ versatile RNA therapeutics and LNP Delivery Systems platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, …

Jun 7, 2024 · Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, …